

Edward Gabrielson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11546888/publications.pdf>

Version: 2024-02-01

118
papers

18,338
citations

20817

60
h-index

21540

114
g-index

120
all docs

120
docs citations

120
times ranked

25378
citing authors

#	ARTICLE	IF	CITATIONS
1	NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. <i>Clinical Cancer Research</i> , 2021, 27, 877-888.	7.0	84
2	Animal Models of Prenatal Stress. <i>Juntendo Medical Journal</i> , 2021, 67, 124-130.	0.1	1
3	CRY ² B2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer. <i>Oncogene</i> , 2021, 40, 5752-5763.	5.9	6
4	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	21
5	Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD ⁺ in sensitive cancer cells. <i>Cancer Biology and Therapy</i> , 2021, 22, 579-586.	3.4	4
6	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 99-111.	13.2	141
7	Proteomic Analysis of the Air-Way Fluid in Lung Cancer. Detection of Periostin in Bronchoalveolar Lavage (BAL). <i>Frontiers in Oncology</i> , 2020, 10, 1072.	2.8	4
8	Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2175-2185.	4.1	8
9	Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. <i>Journal of Hematology and Oncology</i> , 2020, 13, 170.	17.0	25
10	DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 3.	5.2	15
11	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.	7.0	90
12	Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact. <i>Biomarkers in Medicine</i> , 2019, 13, 761-771.	1.4	19
13	DNA Methylation Markers for Breast Cancer Detection in the Developing World. <i>Clinical Cancer Research</i> , 2019, 25, 6357-6367.	7.0	21
14	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2019, 21, 79.	4.4	53
15	Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. <i>Cell Reports</i> , 2019, 27, 491-501.e6.	6.4	73
16	Prognostic Impact of Phosphorylated Discoidin Domain Receptor-1 in Esophageal Cancer. <i>Journal of Surgical Research</i> , 2019, 235, 479-486.	1.6	6
17	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.9	226
18	Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics. <i>Human Pathology</i> , 2019, 84, 18-25.	2.0	5

#	ARTICLE	IF	CITATIONS
19	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. <i>Journal of Clinical Investigation</i> , 2019, 129, 616-630.	8.2	94
20	A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 859-865.	3.7	73
21	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	27.0	1,495
22	Nrf2 signaling and autophagy are complementary in protecting breast cancer cells during glucose deprivation. <i>Free Radical Biology and Medicine</i> , 2018, 120, 407-413.	2.9	39
23	Chemotherapy induces enrichment of CD47 ⁺ /CD73 ⁺ /PDL1 ⁺ immune evasive triple-negative breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1239-E1248.	7.1	238
24	Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. <i>Radiology</i> , 2018, 286, 286-295.	7.3	118
25	Unique pulmonary immunotoxicological effects of urban PM are not recapitulated solely by carbon black, diesel exhaust or coal fly ash. <i>Environmental Research</i> , 2018, 161, 304-313.	7.5	26
26	Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 103-109.	9.6	534
27	De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. <i>FASEB Journal</i> , 2018, 32, 7018-7027.	0.5	33
28	Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts. <i>Clinical Proteomics</i> , 2018, 15, 21.	2.1	15
29	C3a is required for ILC2 function in allergic airway inflammation. <i>Mucosal Immunology</i> , 2018, 11, 1653-1662.	6.0	32
30	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. <i>Modern Pathology</i> , 2017, 30, 530-538.	5.5	92
31	The critical role of EBUS-EBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings. <i>Cancer Cytopathology</i> , 2017, 125, 717-725.	2.4	25
32	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	9.4	706
33	Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. <i>Cancer Cell</i> , 2017, 32, 360-376.e6.	16.8	162
34	The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 2971-2983.	1.8	42
35	Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 64527-64542.	1.8	215
36	Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases. <i>Cancer Cytopathology</i> , 2016, 124, 485-492.	2.4	6

#	ARTICLE	IF	CITATIONS
37	Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases. <i>Human Pathology</i> , 2016, 54, 8-16.	2.0	14
38	Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. <i>EBioMedicine</i> , 2016, 9, 148-160.	6.1	61
39	Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. <i>ACS Chemical Biology</i> , 2016, 11, 3214-3225.	3.4	364
40	Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations. <i>Journal of the American Society of Cytopathology</i> , 2016, 5, 123-132.	0.5	18
41	Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20005-e20005.	1.6	1
42	Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia. <i>Scientific Reports</i> , 2015, 5, 13660.	3.3	11
43	Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer. <i>Epigenetics</i> , 2015, 10, 622-632.	2.7	29
44	Utility of five commonly used immunohistochemical markers TTF1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. <i>Clinical and Translational Medicine</i> , 2015, 4, 16.	4.0	65
45	Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 2887-2900.	3.8	26
46	TBCRC 008: Early Change in ¹⁸ F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 31-37.	5.0	61
47	AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. <i>Oncotarget</i> , 2015, 6, 14754-14765.	1.8	30
48	Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. <i>Oncotarget</i> , 2015, 6, 29143-29160.	1.8	44
49	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. <i>American Journal of Pathology</i> , 2014, 184, 1280-1286.	3.8	250
50	Activation of diverse signalling pathways by oncogenic PIK3CA mutations. <i>Nature Communications</i> , 2014, 5, 4961.	12.8	72
51	The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. <i>Human Pathology</i> , 2014, 45, 926-934.	2.0	51
52	Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program. <i>Cell</i> , 2013, 155, 1639-1651.	28.9	652
53	Aberrant Mucin5B expression in lung adenocarcinomas detected by iTRAQ labeling quantitative proteomics and immunohistochemistry. <i>Clinical Proteomics</i> , 2013, 10, 15.	2.1	18
54	Frequent Inactivation of Cysteine Dioxygenase Type 1 Contributes to Survival of Breast Cancer Cells and Resistance to Anthracyclines. <i>Clinical Cancer Research</i> , 2013, 19, 3201-3211.	7.0	77

#	ARTICLE	IF	CITATIONS
55	Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. <i>Human Pathology</i> , 2013, 44, 1286-1292.	2.0	19
56	Glycoproteomic Analysis of Bronchoalveolar Lavage (BAL) Fluid Identifies Tumor-Associated Glycoproteins from Lung Adenocarcinoma. <i>Journal of Proteome Research</i> , 2013, 12, 3689-3696.	3.7	26
57	Very Long-Chain Acyl-CoA Synthetase 3: Overexpression and Growth Dependence in Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e69392.	2.5	18
58	Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. <i>Journal of Clinical Investigation</i> , 2013, 123, 2921-2934.	8.2	283
59	Digoxin as an inhibitor of global hypoxia inducible factor-1 α (HIF1 α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS1144-TPS1144.	1.6	2
60	Prolonged sulforaphane treatment does not enhance tumorigenesis in oncogenic K-ras and xenograft mouse models of lung cancer. <i>Journal of Carcinogenesis</i> , 2012, 11, 8.	2.5	14
61	Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. <i>Epigenetics</i> , 2012, 7, 701-709.	2.7	59
62	Application of glycoproteomics for the discovery of biomarkers in lung cancer. <i>Proteomics - Clinical Applications</i> , 2012, 6, 244-256.	1.6	26
63	Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. <i>Cancer Cytopathology</i> , 2012, 120, 185-195.	2.4	89
64	Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10509-10509.	1.6	3
65	EGFR and KRAS mutations in metastatic lung adenocarcinomas. <i>Human Pathology</i> , 2011, 42, 1447-1453.	2.0	57
66	Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 119-126.	2.5	69
67	KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. <i>Journal of Human Genetics</i> , 2011, 56, 230-234.	2.3	89
68	High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5384-5389.	7.1	129
69	Mutation of a single allele of the cancer susceptibility gene <i>BRCA1</i> leads to genomic instability in human breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17773-17778.	7.1	134
70	Nuclear Factor- κ B (NF- κ B) Mediates a Protective Response in Cancer Cells Treated with Inhibitors of Fatty Acid Synthase. <i>Journal of Biological Chemistry</i> , 2011, 286, 31457-31465.	3.4	12
71	The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. <i>Cancer Cytopathology</i> , 2010, 118, 441-449.	2.4	93
72	Deletion of <i>Keap1</i> in the Lung Attenuates Acute Cigarette Smoke-Induced Oxidative Stress and Inflammation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 42, 524-536.	2.9	128

#	ARTICLE	IF	CITATIONS
73	High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy. <i>Cancer Biology and Therapy</i> , 2010, 10, 549-554.	3.4	26
74	DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1118-1128.	27.0	546
75	RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy. <i>Cancer Research</i> , 2008, 68, 7975-7984.	0.9	331
76	Inhibiting Fatty Acid Synthase for Chemoprevention of Chemically Induced Lung Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 2458-2464.	7.0	79
77	Selective inhibition of fatty acid synthase for lung cancer treatment. <i>Juntendo Igaku</i> , 2008, 54, 10-15.	0.1	0
78	Coix seed extract, A commonly used treatment for cancer in china, inhibits NF- κ B and protein kinase C signaling. <i>Cancer Biology and Therapy</i> , 2007, 6, 2005-2011.	3.4	80
79	Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment. <i>Clinical Cancer Research</i> , 2007, 13, 7139-7145.	7.0	106
80	Cross-study validation and combined analysis of gene expression microarray data. <i>Biostatistics</i> , 2007, 9, 333-354.	1.5	46
81	FDG-PET for Pharmacodynamic Assessment of the Fatty Acid Synthase Inhibitor C75 in an Experimental Model of Lung Cancer. <i>Pharmaceutical Research</i> , 2007, 24, 1202-1207.	3.5	18
82	Worldwide trends in lung cancer pathology. <i>Respirology</i> , 2006, 11, 533-538.	2.3	124
83	Increased Expression of Mitotic Checkpoint Genes in Breast Cancer Cells with Chromosomal Instability. <i>Clinical Cancer Research</i> , 2006, 12, 405-410.	7.0	237
84	Dysfunctional KEAP1-NRF2 Interaction in Non-Small-Cell Lung Cancer. <i>PLoS Medicine</i> , 2006, 3, e420.	8.4	894
85	Multiple-laboratory comparison of microarray platforms. <i>Nature Methods</i> , 2005, 2, 345-350.	19.0	814
86	Frequent down-regulation of HIVEP2 in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 91, 103-112.	2.5	9
87	Gene Promoter Hypermethylation in Tumors and Plasma of Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2005, 37, 233.	3.0	16
88	Hypermethylation of the GATA Genes in Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7917-7924.	7.0	117
89	Hypermethylation of a Small CpG Guanine-Rich Region Correlates with Loss of Activator Protein-2 Expression during Progression of Breast Cancer. <i>Cancer Research</i> , 2004, 64, 1611-1620.	0.9	67
90	A Cross-Study Comparison of Gene Expression Studies for the Molecular Classification of Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2922-2927.	7.0	196

#	ARTICLE	IF	CITATIONS
91	Induction of spermidine/spermine N 1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N 1,N 11-diethylnorspermine. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 122-126.	2.3	27
92	Hypermethylation in Histologically Distinct Classes of Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5998-6005.	7.0	109
93	Telomere Shortening Occurs in Subsets of Normal Breast Epithelium as well as in Situ and Invasive Carcinoma. <i>American Journal of Pathology</i> , 2004, 164, 925-935.	3.8	133
94	Identification of carboxypeptidase E and $\hat{1}^3$ -glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. <i>Human Pathology</i> , 2004, 35, 1196-1209.	2.0	69
95	Clinical and Biological Relevance of Recently Defi ned Categories of Pulmonary Neoplasia. , 2003, 74, 31-42.		0
96	A neural survival factor is a candidate oncogene in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10931-10936.	7.1	118
97	Molecular markers in ductal carcinoma in situ of the breast. <i>Molecular Cancer Research</i> , 2003, 1, 362-75.	3.4	205
98	Variable Levels of Chromosomal Instability and Mitotic Spindle Checkpoint Defects in Breast Cancer. <i>American Journal of Pathology</i> , 2002, 161, 391-397.	3.8	100
99	A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. <i>Nature Genetics</i> , 2002, 31, 141-149.	21.4	820
100	Mucinous Cancers have Fewer Genomic Alterations than More Common Classes of Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 255-260.	2.5	36
101	Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. <i>Cancer Research</i> , 2002, 62, 3971-9.	0.9	100
102	Methylation of the E-cadherin Gene in Bladder Neoplasia and in Normal Urothelial Epithelium from Elderly Individuals. <i>American Journal of Pathology</i> , 2001, 159, 831-835.	3.8	116
103	Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. <i>Lancet, The</i> , 2001, 357, 1335-1336.	13.7	324
104	Spreadsheet-Based Program for the Analysis of DNA Methylation. <i>BioTechniques</i> , 2001, 30, 110-114.	1.8	16
105	Doublet discrimination in DNA cell-cycle analysis. <i>Cytometry</i> , 2001, 46, 296-306.	1.8	168
106	Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 282-287.	2.8	101
107	Hypermethylation of 14-3-3 $\hat{1}f$ (stratifin) is an early event in breast cancer. <i>Oncogene</i> , 2001, 20, 3348-3353.	5.9	284
108	Functional Genomics, Gene Arrays, and the Future of Pathology. <i>Modern Pathology</i> , 2001, 14, 1294-1299.	5.5	25

#	ARTICLE	IF	CITATIONS
109	Methylation Patterns of the E-cadherin 5' CpG Island Are Unstable and Reflect the Dynamic, Heterogeneous Loss of E-cadherin Expression during Metastatic Progression. <i>Journal of Biological Chemistry</i> , 2000, 275, 2727-2732.	3.4	338
110	Pancreatic Mucinous Cystic Neoplasms with Sarcomatous Stroma: Molecular Evidence for Monoclonal Origin with Subsequent Divergence of the Epithelial and Sarcomatous Components. <i>Modern Pathology</i> , 2000, 13, 86-91.	5.5	62
111	Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors. <i>Journal of the National Cancer Institute</i> , 2000, 92, 564-569.	6.3	1,013
112	Spreadsheet-Based Program for Alignment of Overlapping DNA Sequences. <i>BioTechniques</i> , 1999, 26, 1180-1185.	1.8	6
113	Absence of intragenic mismatch mutations in small cell lung cancers with microsatellite instability. , 1999, 80, 944-945.		1
114	Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. <i>Oncogene</i> , 1998, 16, 2159-2164.	5.9	137
115	Detection of frequent allelic loss of 6q23-q25.2 in microdissected human breast cancer tissues. , 1996, 16, 35-39.		68
116	Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. <i>Nature Genetics</i> , 1995, 11, 210-212.	21.4	593
117	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. <i>Nature Medicine</i> , 1995, 1, 686-692.	30.7	1,812
118	Optimized Cross-Study Analysis of Microarray-Based Predictors. , 0, , 398-422.		1